Remibrutinib

Remibrutinib, a highly selective oral BTKi, has potential to be first targeted therapy approved for CSU in Europe Improvements with remibrutinib observed as early as Week 1 in REMIX 1 & 2, with favorable safety pro no liver safety concerns through Week 52 1 CSU affects nearly 4 million people in Europe, with over 50% of patients remaining symptomatic despite H1-antihistamines 2-4 Basel, February 27, 2026 – Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for remibrutinib. The opinion supports its use as an oral treatment for chronic spontaneous urticaria (CSU) in adult patients with inadequate response to H1‑antihistamine treatment. “The introduction of remibrutinib represents a major advancement, providing clinicians with an oral Bruton’s tyrosine kinase inhibitor (BTKi) treatment, with improvements in symptoms observed as early as Week 1,” said Prof. Dr. med. Martin Metz, Deputy Director, Institute of Allergology, Charité Universitätsmedizin Berlin. “CSU continues to impose a substantial unmet medical need, as many patients struggle to achieve adequate disease control with currently available therapies.” The positive CHMP opinion is supported by results from the pivotal REMIX-1 and REMIX-2 Phase III trials. Remibrutinib showed improvements in itch and hives as early as Week 1, with benefits sustained through Week 52 1 . Improvements in quality of life and sleep were also observed early in treatment 1 . Remibrutinib was well tolerated and demonstrated a favorable safety profile, including no liver safety concerns across both studies through Week 52 1 . “People living with CSU often endure years of frustration, and difficulty being taken seriously. For many, the unpredictable itch flare‑ups can make it hard to sleep, focus on daily responsibilities, or even perform their jobs at times,” said Tonya Winders, President and CEO, Global Allergy & Airways Patient Platform (GAAPP). “The arrival of a new oral treatment option brings us one step closer to ensuring that every person has the opportunity to live fully again.” “Today’s positive CHMP opinion is an important step towards addressing the significant unmet needs of adults living with CSU in Europe,” said Patrick Horber, M.D., President, International, Novartis. “We will continue to collaborate with regulatory authorities globally to make this important medicine, discovered and developed by Novartis, available to patients who need it most.” Following the CHMP recommendation for approval, the European Commission (EC) is expected to issue a final decision within approximately two months. About remibrutinib Remibrutinib is a highly selective, oral BTK inhibitor that blocks the BTK pathway involved in the release of histamine, a key driver of itchy hives (wheals) and swelling 5-7 . By reducing histamine release, remibrutinib helps relieve the symptoms of chronic spontaneous urticaria (CSU) 8,9 . In the US and China, remibrutinib is approved for the treatment of adult patients with CSU who have an inadequate response to H1-antihistamines, under the brand name Rhapsido ® . Remibrutinib has shown positive topline results in chronic inducible urticaria (CIndU) across the three most prevalent subtypes in the pivotal Phase III RemIND trial. It is also being investigated in other immune-mediated conditions, such as hidradenitis suppurativa (HS) and food allergy, in addition to other indications in the company’s Neuroscience portfolio 10 - 14 . About REMIX-1 and REMIX-2 REMIX-1 ( NCT05030311 ) and REMIX-2 ( NCT05032157 ) are two identically designed, global, multicenter, randomized, double-blind, parallel-group, placebo-controlled Phase III trials, consisting of 925 patients who remained symptomatic on second-generation H1-antihistamines. Remibrutinib demonstrated superiority in change from baseline versus placebo in itch (ISS7), hives (HSS7), and weekly urticaria activity (UAS7) at Week 12. Remibrutinib has a demonstrated safety pro requires no lab monitoring. The most common adverse events (incidence ≥3%) were nasal congestion, sore throat, and runny nose (nasopharyngitis), bleeding, headache, nausea, and abdominal pain 1 4 ,1 5 . About chronic spontaneous urticaria (CSU) CSU is the medical term for chronic hives that last for 6 weeks or longer, where the underlying cause is internal rather than exposure to any allergen or external trigger 4,7,1 6 . CSU affects approximately 40 million people worldwide 4,1 7 . It is characterized by the sudden appearance of itchy hives (wheals) and/or deep tissue swelling (angioedema), which can occur on the face, throat, hands, and feet 7,1 8 . CSU affects all ages but occurs most frequently between the ages of 20-40 years, with women affected nearly twice as often as men 7 . CSU causes significant emotional distress, with the majority of patients suffering from sleep deprivation, and high rates of mental disorders, such as anxiety or depression, as well as decreased work productivity 7 . About Novartis Immunology At Novartis, we’re advancing bold science with the goal of bringing relief and a renewed sense of hope to people living with autoimmune diseases. Building on our legacy of first-in-class innovation across rheumatology, dermatology and allergy, and a diverse industry-leading pipeline, we’re committed to shaping what’s next in Immunology. Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn , Facebook , X/Twitter and Instagram . References Metz M, Giménez-Arnau A, Hide M, et al. Long-term efficacy and safety of remibrutinib in patients with chronic spontaneous urticaria in the Phase 3 REMIX-1 and REMIX-2 studies. Presented as a late oral abstract session on clinical trials at EAACI 2024; May 31-June 3, 2024; Valencia, Spain Fricke J, Ávila G, Keller T, Weller K, Lau S, Maurer M, Zuberbier T, Keil T. Prevalence of chronic urticaria in children and adults across the globe: Systematic review with meta-analysis. Allergy. 2020;75(2):423–432. doi:10.1111/all.14037 Worldometer. Europe Population (2025). Available at: [Last accessed February 2026] Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA²LEN task force report. Allergy 2011; 66: 317-330. Maurer M, Berger W, Giménez-Arnau A, et al. Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria. J Allergy Clin Immunol 2022; 150: 1498-1506. Angst D, Gessier F, Janser P, et al. Discovery of LOU064 (remibrutinib), a potent and highly selective covalent inhibitor of Bruton's Tyrosine Kinase. J Med Chem 2020; 63: 5102-5118. Powell RJ, Leech SC, Till S, et al. BSACI guideline for the management of chronic urticaria and angioedema. Clin Exp Allergy 2015; 45: 547-565. Jain V, Giménez-Arnau A, Hayama K, et al. Remibrutinib demonstrates favorable safety pro sustained efficacy in chronic spontaneous urticaria over 52 weeks. J Allergy Clin Immunol 2024; 153: 479-486. Patient. Antihistamines. Last updated 12 October 2022. Available from: [Last accessed: February 2026]. ClinicalTrials.gov. NCT03827798. Study of efficacy and safety of investigational treatments in patients with moderate to severe hidradenitis suppurativa. Available from: . [Last accessed: February 2026] ClinicalTrials.gov. NCT05432388. Study of efficacy, safety and tolerability of remibrutinib in adult participants with an allergy to peanuts. Available from: [Last accessed: February 2026]. ClinicalTrials.gov. NCT05147220. Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis (RMS) (REMODEL-1). Available from: [Last accessed: February 2026]. ClinicalTrials.gov. NCT05156281. Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis (RMS) (REMODEL-2). Available from: [Last accessed: February 2026]. ClinicalTrials.gov. NCT05030311. A Phase 3 study of efficacy and safety of remibrutinib in the treatment of CSU in adults inadequately controlled by H1 antihistamines (REMIX-1). Available from: [Last accessed February, 2026]. ClinicalTrials.gov. NCT05032157. A Phase 3 study of efficacy and safety of remibrutinib in the treatment of CSU in adults inadequately controlled by H1- antihistamines (REMIX-2). Available from: [Last accessed February, 2026]. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy 2022; 77: 734-766. The World Bank. Population, total. Available from: [Last accessed: February 2026]. AAAAI (American Academy of Allergy, Asthma & Immunology). Hives (urticaria) and angioedema overview. Available from: (urticaria)-and-angioedema-overview [Last accessed: February 2026]. # # # Novartis Media Relations E-mail: media.relations@novartis.com Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: investor.relations@novartis.com

⭐强生向 FDA 提交尼卡利单抗 sBLA 申请，寻求其成为首个温抗体型自身免疫性溶血性贫血疗法。尼卡利单抗是一款旨在减少致病性 IgG 自身抗体的 FcRn 阻断剂。目前该药已获 FDA 批准用于治疗全身型重症肌无力（gMG），但尚未获批用于 wAIHA。wAIHA 是一种罕见疾病，目前尚无获批疗法，存在高度未满足的医疗需求。 此次提交得到了 II/III 期 ENERGY 研究（NCT04119050）数据的支持。该研究表明，与安慰剂组相比，接受尼卡利单抗治疗的患者中，有更多患者达到了严格的持久血红蛋白应答主要终点（血红蛋白≥10 g/dL 且较基线增加≥2 g/dL，并持续至少 28 天）。患者的疲劳症状也得到快速且持续的改善。 ⭐诺华瑞米布替尼成为首个在慢性诱导性荨麻疹（CIndU）中达到3期主要终点的疗法，诺华已向FDA提交其用于治疗症状性皮肤划痕症（CIndU 中最常见的类型）补充新药申请（sNDA）。 ⭐礼来公司宣布 LIBRETTO‑432 III 期临床研究取得阳性顶线结果。该研究评估了睿妥®（塞普替尼）作为RET融合阳性肺癌辅助治疗相较于安慰剂的有效性和安全性。LIBRETTO‑432 是目前首个也是唯一一个评估选择性RET激酶抑制剂作为辅助治疗的随机 III 期研究。 ⭐圣因生物SGB-9768（C3 siRNA）再获FDA孤儿药资格认定，用于罕见肾病IC-MPGN ⭐GSK的IBAT口服抑制剂利奈昔巴特片在中国申报上市，治疗原发性胆汁性胆管炎（PBC）成人患者的胆汁淤积性瘙痒。该产品此前已经被纳入优先审评 ⭐三生国健IL-4Rα 单抗SSGJ-611申报上市，用于治疗外用药控制不佳或不适合外用药治疗的成人中重度特应性皮炎（AD） 🤝21亿美金！诺和诺德重金押注口服减肥降糖新药 2月25日，诺和诺德与Vivtex公司宣布达成合作协议，共同开发用于肥胖症、糖尿病及相关并发症的下一代口服生物制剂。根据协议，Vivtex将向诺和诺德授权其部分口服药物递送技术，并有资格获得最高达21亿美元的预付款、研究资金和里程碑付款，以及未来产品销售的分级特许权使用费。 Vivtex Corporation是一家致力于变革治疗药物口服递送的生物技术公司。该公司由麻省理工学院科学家创立，开发了一个机器人驱动平台，整合了其专有的GI-ORIS™高通量筛选系统——一种\x26quot;芯片上的胃肠道\x26quot;——以及已在《自然·生物医学工程》上发表的完整胃肠道组织机器人接口，结合人工智能驱动的计算建模，设计和优化包括生物制剂在内的口服递送治疗药物，以实现可预测的人体表现。